07:35 AM EDT, 08/11/2026 (MT Newswires) -- EQT's (EQT.ST) EQT Life Sciences invested $17.5 million in Vaderis Therapeutics as part of the Swiss biopharmaceutical company's $152 million Series B funding round. The funds will support the launch of a global Phase 3 study for engasertib, a potential first treatment for hereditary hemorrhagic telangiectasia, a rare genetic vascular disease, according to a Tuesday release. The Swedish private equity group co-led the round alongside Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, Perceptive Advisors, Kalehua Capital and returning investors Medicxi and Droia.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.